SOURCE-LINKED STUDY SUMMARY
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Abstract summarizedQuality not appraised
- What was studied
- Two phase 3 randomized trials comparing tirzepatide with placebo for obstructive sleep apnea and obesity.
- Who / model studied
- Adults with moderate-to-severe sleep apnea and obesity, studied for 52 weeks. One trial enrolled people without airway-pressure therapy at baseline; the other enrolled users. Participant counts are not stated.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary breathing-disruption measure fell 25.3 versus 5.3 events per hour in the first trial, and 29.3 versus 5.5 in the second. Secondary outcomes, including weight, sleep symptoms and systolic blood pressure, also improved. Digestive adverse events were most frequent and generally mild or moderate.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2404881